Next generation PI3K alpha inhibitor - OnKure Therapeutics
Alternative Names: Phosphatidylinositol 3-kinase alphaH1047R inhibitor - OnKure Therapeutics; PI3KαH1047R inhibitor - OnKure TherapeuticsLatest Information Update: 06 May 2024
At a glance
- Originator OnKure Therapeutics
- Class Antineoplastics
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 26 Apr 2024 Preclinical trials in Breast cancer in USA (unspecified route) prior to April 2024 (OnKure Therapeutics pipeline, April 2024)